12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Wednesday's pre-market session, several healthcare stocks showed significant movement. Lixte Biotechnology, Nutriband, NovoCure, Strata Skin Sciences, Nuvation Bio, and MediciNova were among the gainers, with Lixte Biotechnology leading with a 67.2% increase. On the downside, Akili, OpGen, Mesoblast, Altimmune, Concord Medical Services, and PDS Biotechnology experienced declines, with Akili seeing the largest drop of 20.6%. Notably, Strata Skin Sciences, Altimmune, and PDS Biotechnology released their Q4 earnings reports.

March 27, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Akili's stock decreased by 20.6% in pre-market trading, with a market cap of $23.7 million.
The significant drop in AKLI's stock price suggests negative sentiment or disappointing news affecting investor confidence.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Altimmune stock declined by 12.72% to $7.55, coinciding with their Q4 earnings release.
The decline in ALT's stock price following their earnings report indicates a negative market reaction to their Q4 financial performance.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 80
NEGATIVE IMPACT
PDS Biotechnology shares decreased by 12.28% to $3.93 after their Q4 earnings were announced.
The decrease in PDSB's stock price after the earnings announcement suggests investor disappointment with their Q4 results.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 80
POSITIVE IMPACT
Lixte Biotechnology shares surged 67.2% in pre-market trading, with a market value of $8.4 million.
The substantial increase in LIXT's share price indicates strong investor interest, potentially due to positive developments or expectations.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Strata Skin Sciences shares increased by 14.93% to $0.53, following the release of their Q4 earnings report.
The increase in SSKN's share price post-earnings suggests the market reacted positively to their Q4 financial results.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 80